Geeta Vemuri


Geeta Vemuri serves as Managing Partner at Baxalta Ventures. She also serves as the Board Member at Aptinyx, as Vice President at Baxter Ventures, as the Board Member at Syntimmune and as a Partner of Quaker BioVentures.

She joined Quaker BioVentures as a Senior Associate in 2003 and was promoted to Partner in 2008. She is a former board member of Protez Pharmaceuticals, which was recently sold to Novartis and is also a current member of the Board of Directors at Argolyn BioSciences, Cellatope, Opsona Therapeutics and Immune Control. She is a Board Observer for Optherion, Regado, Tengion and Tranzyme.

Prior to Quaker, Dr. Vemuri was an Associate at Toucan Capital. Dr. Vemuri has also served as an Associate Analyst at Salomon Smith Barney. Earlier in her career, she was a Research Scientist at The Wistar Institute and postdoctoral fellow at Thomas Jefferson University. Dr. Vemuri received her M.S. from Central University in India, her Ph.D. in biochemistry from the Indian Institute of Sciences and her M.B.A. from the Wharton School of the University of Pennsylvania. She currently serves on the Board of Directors of Gliknik and Executive Committee of Southeast BIO and the Advisory Committees of BioAdvance Greenhouse and

Current Board Responsibilities: Argolyn, Cellatope, and Protez Pharmaceuticals. Board Observer Responsibilities: Immune Control, Optherion, Regado Biosciences, Tengion, and Tranzyme Pharma.

Other: Advisory Committee of the Sid Martin Biotechnology Incubator, Board of Directors and Executive Committee of Southeast BIO, the Advisory Committee of BioAdvance Greenhouse, and the Selection Committee for the "Best Incubator Company of the Year" Awards for companies located in Maryland.

Education: M.S. from Central University in India, Ph.D. in Biochemistry from Indian Institute of Sciences, and M.B.A. from the Wharton School of the University of Pennsylvania

Fund's investment verticals: therapeutic, diagnostic, medical device, hematology, immunology, inflammation, oncology and software.